Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Controlled Phase 2a/b Study of the Efficacy and Safety of PEG-rIL-29 Administered in Combination With Ribavirin to Treatment-Naive Subjects With Chronic Hepatitis C Virus Infection

NCT01001754 is registered in ClinicalTrials.gov with ZymoGenetics as lead sponsor.

NCT NCT01001754
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01001754 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Controlled Phase 2a/b Study of the Efficacy and Safety of PEG-rIL-29 Administered in Combination With Ribavirin to Treatment-Naive Subjects With Chronic Hepatitis C Virus Infection
Lead sponsor
ZymoGenetics
Phase
Phase 2
Overall status
Unknown status
Start date
May 31, 2010
Completion date
May 31, 2012
Enrollment
600 (estimated)
Sites
79

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c, chronic